Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Beneficial effects of chronic mexiletine treatment in a human model of SCN5A overlap syndrome

1 Jun 2023

Abstract excerpt

AIMS: SCN5A mutations are associated with various cardiac phenotypes, including long QT syndrome type 3 (LQT3), Brugada syndrome (BrS), and cardiac conduction disease (CCD). Certain mutations, such as SCN5A-1795insD, lead to an overlap syndrome, with patients exhibiting both features of BrS/CCD [decreased sodium current (INa)] and LQT3 (increased late INa). The sodium channel blocker mexiletine may acutely...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cardiac Arrhythmias and Treatments
Share to Cardiac electrophysiology and arrhythmias
Share to Ion channel regulation and function

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 37369559
DOI: 10.1093/europace/euad154

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Beneficial effects of chronic mexiletine treatment in a human model of SCN5A overlap syndromePMID 37369559Read ↗

Mexiletine rescues a mixed biophysical phenotype of the cardiac sodium channel arising from the SCN5A mutation, N406K, found in LQT3 patients.Semantic proximity Read ↗

Anti-arrhythmic potential of the late sodium current inhibitor GS-458967 in murine Scn5a-1798insD+/- and human SCN5A-1795insD+/- iPSC-derived cardiomyocytes.Semantic proximity Read ↗

Trafficking defects and gating abnormalities of a novel SCN5A mutation question gene-specific therapy in long QT syndrome type 3.Semantic proximity Read ↗

A trafficking defective, Brugada syndrome-causing SCN5A mutation rescued by drugsSemantic proximity Read ↗

Cardiomyocytes derived from pluripotent stem cells recapitulate electrophysiological characteristics of an overlap syndrome of cardiac sodium channel disease.Semantic proximity Read ↗

Complex interactions in a novel SCN5A compound mutation associated with long QT and Brugada syndrome: Implications for Na+ channel blocking pharmacotherapy for de novo conduction disease.Semantic proximity Read ↗

Reduced current density, partially rescued by mexiletine, and depolarizing shift in activation of SCN5A W374G channels as a cause of severe form of Brugada syndrome.Semantic proximity Read ↗

Ranolazine for Congenital Long-QT Syndrome Type III: Experimental and Long-Term Clinical Data.Semantic proximity Read ↗

Partial expression defect for the SCN5A missense mutation G1406R depends on splice variant background Q1077 and rescue by mexiletineSemantic proximity Read ↗

Phenotypic overlap of cardiac sodium channelopathies: individual-specific or mutation-specific?Semantic proximity Read ↗

Human iPS cell model of type 3 long QT syndrome recapitulates drug-based phenotype correction.Semantic proximity Read ↗

Expression Defects of SCN5A Common Polymorphisms S524Y and H558R in the Q1077 Splice Variant Can Be Rescued by Mexiletine.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.